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Members of the Notch family of transmembrane receptors, Notch1-4 in mammals, are involved in the
regulation of cell fate decisions and cell proliferation in various organisms. The Notch4 isoform, which is
specific to mammals, was originally identified as a viral oncogene in mice, Int3, able to initiate mammary
tumors. In humans, Notch4 expression appears to be associated with breast cancer stem cells and endocrine
resistance. Following ligand binding, the Notch4 receptor undergoes cleavage at the membrane and the
Notch4-intracellular domain (ICD), translocates to the nucleus and regulates gene transcription. Little is
known on the mechanisms regulating Notch4-ICD and its nuclear localization. Here, we describe the
identification of four distinct AKT phosphorylation sites in humanNotch4-ICD and demonstrate that AKT
binds Notch4-ICD and phosphorylates all four sites in vitro and in vivo. The phosphorylation in cells is
regulated by growth factors and is sensitive to phosphatidyl inositol-3 kinase (PI3K) inhibitors. This
phosphorylation generates binding sites to the 14-3-3 regulatory proteins, which are involved in the
regulation of nucleocytoplasmic shuttling of target proteins, restricting phosphorylated Notch4-ICD to the
cytoplasm. Our findings provide a novel mechanism for Notch4-ICD regulation, suggesting a negative
regulatory role for the PI3K-AKT pathway in Notch4 nuclear signaling.
T
he evolutionarily conserved Notch family of transmembrane receptors are involved in the regulation of cell
fate decisions and cell proliferation via their activity as transcriptional regulators1. Canonical Notch signal-
ing is mediated by the transcription factor CSL (CBF-1, Suppressor of Hairless, Lag-1), also known as RBP-
Jk. Mammals express four Notch genes, Notch1-4, with distinct functions and regulation, though there is some
functional redundancy2,3. Notch4, which is specific to mammals, was initially identified as a truncated oncogenic
form in mice, Int3, able of initiating mammary tumors4,5. The oncogenic activity of Notch4-ICD in transgenic
mice has been shown to be independent of CSL, and thus presumably requires a yet to be identified non-canonical
signaling pathway6. In humans, Notch4 overexpression is associated with breast cancer stem cells and with
endocrine resistance in estrogen-receptor a (ERa)-positive breast cancer7,8. In normal development, Notch4
expression appears to be restricted to endothelial cells9–11, where it regulates vascularization during development,
as well as endothelial cell function and response to inflammation11–14. It has also a role in tumor angiogenesis and
blood vessel perfusion15,16.
Activation of Notch receptors is initiated by the binding of transmembrane ligands on adjoining cells, such as
Delta and Serrate/Jagged families to the Notch receptor, leading to its sequential cleavage and the release of the
intracellular domain, designated Notch-ICD17. This fragment translocates to the nucleus and participates in the
formation of specific transcriptional complexes1,18,19. Much of what is known about Notch signaling derives from
studies of Notch1 and Notch2, the most conserved paralogs. Non-canonical, non-nuclear signaling has been
described for Notch1 in T-cells. Specifically, Notch1 has been reported to signal through AKT via mTORC2 and
to NF-kB via the IKK signalosome and nuclear IKKa20–23. Notch-ICD is a relatively short-lived protein and
undergoes rapid degradation through an ubiquitin-mediated pathway. The pathways that regulate the stability of
Notch-ICDs other thanNotch1 as well as the protein complexes they form are still poorly defined. Specifically, the
regulation of Notch4-ICD by phosphorylation or other post-translational modifications or by interaction with
adapter proteins, which are key regulators ofmany other transcriptionmodulators, is largely unknown24. A recent
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study demonstrated direct interaction of p53 and Mdm2 with
Notch4-ICD, leading to Notch-4 degradation by an ubiquitin-
mediated pathway25. Conversely, Mdm2 has been reported to activ-
ate Notch1-ICD26. Elongin C complexes were also shown to regulate
Notch4-ICD degradation in connection with diabetic kidney fib-
rosis27. Several signaling pathways, including the PI3K-AKT path-
way, have been shown to crosstalk with Notch family members
(Notch1 and 3), however, the mechanistic aspects of this crosstalk
have not been defined28,29.
Here, we describe the identification of four distinct AKT phos-
phorylation sites in human Notch4-ICD and demonstrate that these
sites are phosphorylated by AKT in vitro and in vivo. In turn, these
phosphorylations generate binding sites for the regulatory 14-3-3
scaffold proteins. The Notch4-ICD-14-3-3 binding in cells is regu-
lated by growth factors and is dependent on the PI3K-AKT pathway.
This regulatory network controls the nuclear localization of Notch4-
ICD by excluding the phosphorylated Notch4-ICD from the nucleus
and thus potentially restricting its transcriptional activity. The iden-
tified regulatory mechanism is specific for Notch4 since the other
Notch family members do not contain any AKT phosphorylation
sites. Our results detail a new regulatory mechanism specific for
controlling Notch4 ICD localization, defining a potential regulation
of Notch4 function by growth factors and other signals that activate
AKT.
Results
Notch4-ICD contains AKT consensus phosphorylation sites and
binds AKT. The four mammalian Notch receptors show significant
variations in their extracellular and intracellular domains2. To
explore potential differences in their regulation by phosphory-
lation, we analyzed the four mammalian Notch receptors for the
presence of phosphorylation motifs using the Motif Scan program
(http://scansite.mit.edu)30 that predicts protein phosphorylation
sites and protein interaction motifs. This analysis revealed the
presence of four consensus AKT phosphorylation sites in human
Notch4-ICD: S1495, S1847, S1865 and S1917 (Fig 1A). These sites
are not conserved in the other Notch receptors, suggesting a specific
mechanism for Notch4 regulation by AKT. Interestingly, these four
sites are fully conserved in primates, but are only partially conserved
in other mammals, including rodents and larger mammals (Supple-
mentary Fig 1 and data not shown), pointing to a somewhat
distinctive mechanism for the regulation of human and primate
Notch4 proteins.
To determine the physiological relevance of the identified sites, we
examined the interaction of AKT and Notch4-ICD in vivo using co-
transfection experiments and GST-pull-downs (Fig 1B and C). We
found extensive Notch4-ICD co-purification with GST-AKT but not
with GST control (Fig 1B, compare lanes 1–6 with 7–12), dem-
onstrating specific binding and indicating on physical interaction
between AKT and Notch4-ICD. Interestingly, in contrast to several
other AKT targets, such as the FoxO transcription factors that
require AKT activation for binding31,32, AKT binding to Notch4
was not dependent on AKT activity (Fig 1C, BEZ-235 treatment)
or the presence of the AKT phosphorylation sites on Notch4
(Fig 1B, compare lane 7 with 8–12 and Fig 1C, lanes 6,7 with 8–
15), suggesting that AKT constitutively binds to Notch4-ICD.
AKT phosphorylates Notch4-ICD in vitro and in vivo. To
determine whether AKT can directly phosphorylate Notch4-ICD,
we performed in vitro kinase assays using purified AKT and either
Figure 1 | Human Notch4-ICD contains four putative AKT phosphorylation sites and binds AKT in vivo. (A) The human Notch4 protein sequence
(accession # AAC32288) was analyzed using the Motif Scan program. Presented are the results of the analysis for AKT phosphorylation and 14-3-3
binding sites in the ICD domain. Note the overlap between the 14-3-3 binding sites and the AKT phosphorylation sites. (B & C) COS-7 cells were
transfected with GST control or GST-AKT together with FLAG-Notch4-ICD or its mutants as indicated. Exponentially growing cells (B) or cells treated
with vehicle or 10 nM of the PI3K inhibitor BEZ235 (C) were analyzed for FLAG-Notch4-ICD recovery in GST pull-downs by FLAG immunoblotting.
GST and GST-AKT protein recoveries were analyzed by coomassie staining (B). Notch4-ICD expression and AKT phosphorylation (S473) were analyzed
in total cell lysates. WT: wildtype; 2XA: S1495/1847A; 3XA: S1495/1847/1865A; 4XA: S1495/1847/1865/1917A.
www.nature.com/scientificreports
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wildtype Notch4-ICD or mutant forms substituted with alanines at
the predicted AKT phosphorylation sites (Fig 2A). These experi-
ments showed that AKT can directly phosphorylate Notch4-ICD
and that all four identified sites contribute to the phosphorylation
in vitro. AKT did not phosphorylate a mutant form lacking all four
sites (Fig 2A, compare lanes 3 and 11), indicating that the identified
sites are the only Notch4-ICD sites phosphorylated by AKT in vitro.
In order to study the regulation of Notch4-ICD phosphorylation
on the identified sites in vivo, we developed phosphospecific anti-
bodies for each of the phosphorylation sites (Fig 2B, C and D). We
were successful in obtaining site-specific antibodies with minimal
cross-reaction with unphosphorylated Notch4 or among the four
AKT phosphorylation sites (Fig 2B, C and D). Using these antibod-
ies, we found that all the four predicted Notch4-ICD sites are phos-
phorylated in vivo. Importantly, reactivity with these antibodies
required cell stimulation with growth factors (e.g., EGF) pointing
to the dependency of the phosphorylation on the PI3K-AKT path-
way (Fig 2 B, C and D, compare lanes 2 and 3).
AKTphosphorylation promotes Notch4-ICD interaction with 14-
3-3f. AKT phosphorylation of target proteins often generates bind-
ing sites for the 14-3-3 adaptor protein family, and in many cases,
14-3-3 binding rather than the phosphorylation itself is responsible
for regulating the function of the target protein32–35. Indeed, theMotif
Scan analysis identified several consensus 14-3-3 binding sites in
Notch4-ICD, overlapping with the AKT phosphorylation sites at
S1495, S1865 and S1917 (Fig 1A). The site surrounding S1495
showed the strongest 14-3-3 binding consensus from all three sites,
suggesting it could serve as the primary 14-3-3 binding site. To
examine whether 14-3-3 binds to Notch4-ICD, we used similar
GST-pull-down experiments as with AKT, demonstrating in vivo
interaction between 14-3-3f and Notch4-ICD (Fig 3A). The
binding was induced by growth factor treatment and was sensitive
to PI3K inhibition (Fig 3A and B), indicating regulation through the
PI3K-AKT pathway. The binding was also dependent on the AKT
phosphorylation sites, as individual mutation of the AKT phospho-
rylation sites decreased the binding to 14-3-3 andmutation of all four
Figure 2 | AKTphosphorylates Notch4-ICDon four distinct sites in vitro and in vivo. (A) The indicated FLAG-Notch4-ICD forms andHA-FoxO3were
purified by immunoprecipitation fromHEK-293T cells and incubated alone or with active AKT in a kinase reactionmixture.32P incorporation inNotch4-
ICD and FoxO3 were quantified by phospho-imaging (top panel). Notch4-ICD recovery was visualized by FLAG immunoblotting. (B–D) Protein
extracts from COS-7 cells expressing the indicated FLAG-Notch4-ICD forms, treated with vehicle or EGF (100 ng/ml for 15 min), were immunoblotted
with the indicated phospho-Notch4 antibodies or pre-immune rabbit serum (B). Indicated are the migration points of Notch4-ICD and the 105 kDa
protein marker (B).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8782 | DOI: 10.1038/srep08782 3
sites completely eliminated the binding (Fig 3C). The results also
showed that the site surrounding S1495 is the main binding site,
since mutation of this site resulted in the most marked reduction
in 14-3-3 binding compared to all other single mutations (Fig 3C,
compares lanes 10 and 11 with 13–15). Supporting this notion,
mutation of proline 1497 diminished 14-3-3 binding (Fig 3C, lane
12), consistent with the dependency of 14-3-3 proteins on proline at
the 12 position of the phosphorylated residue for optimal bind-
ing31,36. 14-3-3 proteins bind their targets as dimers. The binding is
facilitated by the presence of two or more binding sites on the target
proteins and usually depends on one optimal site for the initial
interaction, which then facilitates the binding of the other chain to
less optimal sites34,36. Our results suggest that the site at S1495 serves
as this initial interaction site and that the other, less optimal sites,
serve as the secondary interaction points. Interestingly, this site is
only present in primates but is not conserved in other mammals
Figure 3 | AKT phosphorylation promotes Notch4-ICD binding to 14-3-3f. (A & B) COS-7 cells were transfected with GST control or GST-14-3-3f
together with FLAG-Notch4-ICD as indicated. Cells were treated with vehicle or 100 ng/ml EGF for 15 min (A) or for the indicated periods (B) or
with 10 nM of BEZ235 for the indicated periods (B). Samples were analyzed for FLAG-Notch4-ICD recovery in GST pull-downs by FLAG
immunoblotting. GST and GST-14-3-3f protein recoveries were analyzed by GST immunoblotting. Notch4-ICD expression and AKT phosphorylation
were analyzed in total cell lysates. (C) The indicated FLAG-Notch4-ICD forms were coexpressed with GST or GST-14-3-3f in HEK-293T cells and FLAG-
Notch4-ICD recovery in GST pull-downs was examined as in A & B. Note that HEK293T cells have constitutive activation of AKT, allowing constitutive
GST-14-3-3-Notch4-ICD interaction.
www.nature.com/scientificreports
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Figure 4 | AKT-phosphorylated Notch4-ICD is restricted to the cytoplasm. (A) COS-7 cells expressing FLAG-Notch4-ICD were treated with 10 mMof
the PI3K inhibitor LY 294002 for 1 h or with 100 ng/ml EGF for 15 min and cells were fractionated for nuclear and cytoplasmic fractions. Equal amount
of nuclear and cytoplasmic protein was analyzed by immunoblotting using the indicated antibodies. Note the exclusion of phosphorylated-Notch4-ICD
from the nuclear fraction (top panel). (B) 14-3-3-Notch4 association was analyzed in COS-7 cells co-expressing GST-14-3-3f and HA-Notch4-DhN4
(Notch4 form that contains the transmembrane region and parts of the extracellular domain and requires proteolytic cleavage for releasing the ICD
domain). Cells were treated as indicated with the c-secretase inhibitor BMS-708163 (GSI, 1 mM for 1 h), EGF (100 ng/ml for 15 min) or their
combination. Note that the GSI treatment increased Notch4-14-3-3 association without affecting the AKT activation level. (C) Amodel for Notch4-ICD
regulation byAKT and 14-3-3. Based on our results, we propose that AKT is constitutively associated withNotch4 at themembrane in basal conditions. In
this situation, activation ofNotch4 by one of its ligands will result in the release of active Notch4-ICD that will translocate to the nucleus and participate in
gene regulation. Whether AKT is bound to Notch4-ICD in the nucleus remains to be determined. In growth factor-activated cells or cancer cells with
constitutive AKT activation, Notch4-ICD is phosphorylated by AKT and is bound to 14-3-3 at the membrane. Notch4 receptor activation results in
release of Notch4-ICD, however, 14-3-3 restricts its translocation to the nucleus and participation in gene regulation.
www.nature.com/scientificreports
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(Supplementary Fig 1 and data not shown), suggesting that the 14-3-
3-mediated regulation of Notch4-ICD is somewhat unique to
primates.
AKT-phosphorylated Notch4-ICD is restricted to the cytoplasm.
14-3-3 binding can regulate the function of its targets by several
mechanisms: it can affect stability and dephosphorylation, increase
or decrease enzymatic activity and alter subcellular localization33. In
the case of FoxO transcription factors, for example, 14-3-3 proteins
have been shown to exert all three functions: restricting their nuclear
localization, obstructing their binding to DNA and stabilizing the
phosphorylated form31,32,37. To determine the effects of AKT
phosphorylation and the concomitant 14-3-3 binding on Notch4-
ICD localization, we fractionated cells into cytoplasmic and nuclear
fractions and examined the presence of total and phosphorylated
Notch4-ICD in the fractions (Fig 4A). These experiments demon-
strated that the phosphorylated Notch4-ICD was present only in the
cytoplasm, while total Notch4-ICD was both in the cytoplasm and
the nucleus (Fig 4A). These results were similar to our results with
FoxO transcription factors, suggesting that the AKT-14-3-3 network
acts to restrict the translocation of Notch4-ICD to the nucleus. To
examine whether 14-3-3 binding to theNotch4-ICD occurs before or
after cleavage of the receptor, we examined the binding of 14-3-3 to
Notch4-DhN4, which contains the transmembrane domain and is
anchored in themembrane (Fig 4B).We obtained a robust binding of
14-3-3 to this Notch4 form and the binding was stabilized by treating
the cells with c-secretase inhibitors that block cleavage of the
Notch4-ICD domain (Fig 4B, compare lanes 1 and 2). The results
suggest that Notch4 phosphorylation by AKT and the binding of 14-
3-3 occur already at the membrane before the cleavage of the ICD
domain.
Discussion
The results presented in this study suggest a novel mechanism for the
posttranslational regulation of Notch4-ICD (Fig 4C). This regulation
involves the binding of inactive AKT to Notch4, possibly at the
membrane, and phosphorylation of Notch4-ICD upon AKT activa-
tion. This phosphorylation in turn generates binding sites for the
regulatory 14-3-3 proteins. Our data suggests that the Notch4-ICD
could be pre-bound to 14-3-3 before cleavage and that 14-3-3 bind-
ing restricts the phosphorylated Notch4-ICD to the cytoplasm. It
remains to be determined whether 14-3-3 binding also restricts the
incorporation of Notch4-ICD into active transcriptional complexes
or its association with chromatin by masking the RAM domains on
Notch4-ICD andwhether it has a role in controlling the Notch4-ICD
half-life by affecting its degradation. The physiological function of
phosphorylated, 14-3-3-bound Notch4-ICD remains to be clarified.
It may serve as a reservoir to be mobilized after another signal trig-
gers its dephosphorylation, and/or it may signal through non-canon-
ical, cytoplasmic pathways.
Our findings have potentially strong implications to understand-
ing normal developmental processes that involve Notch4 function as
well as cancer pathogenesis by providing a novel link between insulin
and growth factor-activated AKT signaling and the transcriptional
regulator Notch4. AKT is activated in 50% of breast and prostate
cancers and promotes tumorigenesis by teaming with 14-3-3 to regu-
late key proteins involved in cellular transformation, such as FoxO
transcription factors, the pro-apoptotic protein BAD and the cell
cycle regulator p27Kip1 among others. To explore whether this
crosstalk may operate in human breast cancer, we examined the
well-characterized Nottingham-Tenovus breast cancer cohort
TMA (n 5 1079) by immunohistochemistry for pAKT (S473) and
Notch4 (unpublished observation). Interestingly, pAKT correlated
inversely with high nuclear Notch4 (Pearson Chi square p5 0.023)
and directly with cytoplasmic Notch4 (p5 0.036). This suggests that
the mechanism we have uncovered may operate in breast cancer.
Notch inhibitors, as well as PI3K and AKT inhibitors, are in clinical
trials, but their optimal use, as for other targeted drugs, will require
mechanism-based combinations. Though there is strong evidence
that Notch receptors cooperate with the PI3K-AKT pathway in
breast cancer, the mechanism of this crosstalk and thus the potential
therapeutic implications of combining their inhibitors is not well
defined. Our data suggests that AKT inhibition may result in release
of Notch4-ICD from 14-3-3 and increased nuclear Notch4 signaling.
The possible role of this pathway in the non-canonical oncogenic
activity of Notch4-ICD remains to be determined. Interestingly,
mammary mouse tumors caused by expression of Notch4-ICD dis-
play high levels of pAKT and pMEK, and cell lines derived from these
tumors require PI3K and ERK activities for anchorage-independent
growth38. However, whethermurineNotch4 is also regulated byAKT
and/or 14-3-3 through partially conserved sites (Supplementary Fig
1) remains to be determined.
Based on our data, it is also possible that Notch4-ICD may act as
an AKT scaffold, facilitating AKT signaling and potentially trans-
porting AKT into the nucleus. Evidence also exists that Notch4 is
essential for the maintenance of the elusive breast cancer stem cells.
Thus, the identification of Notch4 as a direct AKT target could
provide a breakthrough in understanding Notch4 regulation and
highlight a rationale for combiningNotch4 andAKT targeting drugs.
Methods
cDNA constructs, antibodies and inhibitors. pEBG-GST-AKT, pEBG-GST-14-3-
3f and pcDNA3.1-HA-FoxO3 were as previously described31. pCDNA3-FLAG-
Notch4-ICD and pCDNA3-HA-Notch4-DhN4 were gifts from Brian Nickoloff
(present address: Michigan State University Medical School) and Keith Brennan
(University of Manchester). The QuikChange site-directed and the multi-site-
directed mutagenesis kits (Stratagene) were used to generate the Notch4-ICD
mutants: S1495A, P1497A, S1847A, S1865A, S1917A and their combinations: S1495/
1847A (2XA), S1495/1847/1865A (3XA), S1495/1847/1865/1917A (4XA) and were
confirmed by full-length sequencing. Pan-AKT, p-S473-AKT, GST, GAPDH and
Lamin B1 antibodies were from Cell Signaling Technology. FLAG was from Sigma.
HA antibody was produced using the 12CA5 hybridoma. Phosphospecific antibodies
for Notch4-S1495, S1847, S1865 and S1917 were generated by Twentyfirst Century
Biochemicals (Marlboro, MA). LY294002, BEZ235 and BMS-708163 were from
Selleck Chemicals.
Cell culture and transfection.HEK-293T and COS-7 cells were maintained in high-
glucose DMEM media (Invitrogen), supplemented with 10% Fetal Bovine Serum in
5% CO2. Transient transfections were performed using FuGENE HD (Roche)
according to the manufacturer’s instructions.
Cell extraction, fractionation and western blot analysis. Cellular protein was
extracted in lysis buffer containing 50 mMTris-Cl, pH 7.5, 100 mMNaCl, 1%Triton,
1 mM EDTA, 1 mM EGTA, 1 mM DTT, 50 mM b-glycerolphosphate, 2 mM
Na2VO4 and protease inhibitors and cleared by centrifugation. The NE-PER
fractionation kit (Pierce) was used for nuclear/cytoplasmic fractionation according to
the manufacturer’s instructions. Protein extracts were separated using SDS-PAGE,
transferred to 0.45 uM Immobilon-P PVDF membrane (Millipore) and immuno-
blotted using the indicated antibodies followed by ECL. The blots were analyzed using
ChemiDoc digital imaging system (BioRad).
Immunoprecipitation and protein binding assays. Cells expressing the indicated
vectors were lysed and proteins were extracted as detailed above. Equal amounts of
protein (1–2 mg/point) were incubated with protein A/G agarose beads (Santa Cruz
Biotechnology) coupled with the appropriate antibody or with GSH sepharose beads
(Amersham/GE Healthcare) for GST purification for 90 minutes followed by 2X
washes with lysis buffer, 1X wash with lysis buffer containing 0.5 M LiCl and 2X
washes with buffer containing 40 mM Tris-Cl, pH 7.5, 0.1 mM EDTA and 5 mM
MgCl2. For the last wash, the beads were transferred to a new tube and the proteins
were eluted using SDS-PAGE sample buffer at 95uC for 5 minutes. Total cell extracts
from each sample were saved to examine protein expression and pathway activation/
inhibition.
In vitro kinase assay. HA-FoxO3, FLAG-Notch4-ICD and the indicated Notch4
mutants were purified by HA or FLAG-immunoprecipitation from HEK-293T cells
expressing the corresponding vectors and the agarose beads were incubated with
200 ng active GST-AKT that was affinity-purified from HEK-293T cells using GSH
purification. The kinase assays were performed in a kinase buffer containing 40 mM
Tris-HCl, pH 7.5, 0.1 mM EDTA, 5 mM MgCl2, 2 mM dithiothreitol and 100 mM
ATP supplemented with [c-32P]ATP (10 mCi/reaction) at 30uC for 20 min. HA-
FoxO3 served in the experiments as a positive AKT substrate control.
www.nature.com/scientificreports
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